16th International Adenovirus Meeting (IAMXVI)
We are delighted to announce our 16th International Adenovirus Meeting (#IAMXVI) will take place in Cardiff, the capital city of Wales.
Cardiff is a vibrant and dynamic city that is steeped in history, myths and legends (and the Welsh do love a dragon, hence the IAM XVI logo). The iconic Cardiff Castle which adorns the city centre dates back to AD55, making it almost 2000 years old. Cardiff is also well known as the birthplace of children’s author Roald Dahl, its iconic green spaces such as Bute Park, and its arcades – many of which date back to Edwardian and Victorian times.
It is a great pleasure to welcome the adenovirus community to our sunny capital city in south Wales. We hope you will enjoy your time here, and may even extend your stay to explore the many beautiful beaches and rugged coastlines of south and west Wales.
Our conference will take place in the Centre for Student Life, next to the main campus of Cardiff University, and half a mile’s walk from Cardiff city centre. This state-of-the-art building provides modern lecture theatres and break-out spaces, with ample space for poster boards, and light and open spaces for networking, sponsors, and serving food and drinks.
The International Adenovirus Meeting is the only conference focusing entirely on the adenovirus, comprising all aspects of their biology, pathology, and biotechnological applications. We warmly invite you to be part of this exciting meeting in Cardiff. Spaces are limited, so we encourage you to register early.
We look forward to giving you a huge Welsh welcome in Cardiff, sharing exciting advancements in adenoviral biology, making new collaborations and creating great memories together.
Topics
The topics covered during the conference will include:
- structure and assembly
- receptors, entry and trafficking
- translation and gene therapy
- virus-host interactions
- immunology and pathogenesis
- epidemiology
- replication
- oncolytic vectors
- vaccines
- non-human ads, and much more
Programme
- EMBO Keynote Speaker: Professor Urs Greber, University of Zurich
- Microbiology Society Keynote Speaker: Professor David Curiel, Washington University
- The Company of Biologists Keynote Speaker: Professor Anja Ehrhardt, Witten/Herdecke University
View the full programme.
Important dates
| Deadline | Date |
|---|---|
| Early bird registration deadline | 1 February 2025 |
| Abstract deadline | 23 March 2025 |
| Abstract acceptance notification and selection of oral presentations | 9 May 2025 |
| Regular registration deadline | 23 June 2025 (12:00pm UK time) |
| Conference | 7 to 11 July 2025 |
Organisation committee
Professor Alan Parker
Head of Solid Cancers, Professor of Translational Virology, Director of the Wales Applied Virology Unit and HCRW Senior Research Leader.
Dragomira Majhen
Senior Scientist, Ruđer Bošković Institute, Zagreb, Croatia
- dragomira.majhen@irb.hr
- +385 1 456 1145
David T. Curiel
Professor of Radiation Oncology, Washington University School of Medicine, St. Louis
- dcuriel@wustl.edu
- +1 314 747 5443
Registration details
Registration will soon be available, rates are as follows (these do not include accommodation, which must be booked separately):
| Category | Early Bird (up to 1 February 2025) | Regular |
|---|---|---|
| PhD Students | £300 | £400 |
| Academic/postdoc | £550 | £650 |
| Industry | £1,000 | £1,200 |
Accommodation
Accommodation is not included in the price. To provide a budget option we have partnered with Cardiff University to reserve budget accommodation in the student hall, Senghennydd Court.
For hotels, there are a wide range of hotels available in the city centre which is close by and can be booked directly from the relevant websites. We recommend booking early as hotels become scarce and book up in the summer months.
Sponsorship opportunities
Sponsorship packages are available for this event, please email us for a sponsor brochure: IAMXVI@cardiff.ac.uk
Sponsors
Axion BioSystems: Real-Time, Label-Free Solutions for Live-Cell Analysis
Axion BioSystems develops high-performance instruments for real-time, label-free live-cell analysis, empowering researchers across oncology, immunology, neuroscience, cardiology, and stem cell biology.
The Maestro Z Impedance platform provides continuous monitoring of cell health, proliferation, cytotoxicity, immune cell killing, and barrier integrity—all without labels or endpoint assays. Compatible with 2D and 3D cell models, Maestro Z delivers sensitive, noninvasive measurements making it ideal for virology, oncolytic virus, cancer research, and immunotherapy.
The Maestro MEA platform complements impedance analysis with microelectrode array technology to noninvasively record electrical activity from neurons and cardiomyocytes. This enables functional assessment of neural networks, neurotoxicity screening, and cardiac safety testing using iPSC-derived models.
Axion’s Omni Live-Cell Imaging system adds brightfield and fluorescence imaging capabilities for real-time visualization of cell morphology, confluency, and 3D cell culture. Fully automated and incubator-friendly, Omni is well-suited for monitoring cell growth, differentiation, and cytotoxicity interactions over time.
Together, Axion’s Maestro Z, MEA, and Omni platforms provide an integrated solution for dynamic analysis of living cells. Trusted by academic, biotech, and pharmaceutical labs worldwide, these tools accelerate discovery and enhance translational relevance in biomedical research.
Viral Vector Core Facility (VVCF)
Viral Vector Core Facility (VVCF) produces high quality pre-clinical adenovirus and modified vaccinia Ankara (MVA) vectors for academic and industry partners across the world. VVCF is based at the Pandemic Sciences Institute within the Nuffield Department of Medicine at the University of Oxford. Our vectors are used in a wide range of animal models including mice, non-human primates, sheep, cattle and buffalo, pigs, chickens, elephants, goats, camels, rabbits, guinea pigs and rats.
Malvern Panalytical, Micromeritics & SciAps: Your Partners in Discovery
Malvern Panalytical, part of Spectris plc, is a global leader in advanced material characterization. Together with Micromeritics and SciAps, we deliver a powerful portfolio of complementary technologies that enable the world’s most innovative companies, academic institutions, and government laboratories to accelerate scientific discovery and improve product development.
Our solutions are trusted in over 92,000 laboratories worldwide. Scientists value our instruments for their precision, reliability, and the depth of expertise we bring as true partners in research.
For adenovirus researchers and the broader gene therapy community, our technologies help address critical challenges—whether characterizing viral vectors, optimizing purification workflows, or ensuring product stability and consistency. Malvern Panalytical instruments measure particle size, concentration, and zeta potential, as well as biomolecular interactions, thermal stability, and crystallographic structure—supporting every stage of vector design and manufacturing.
Micromeritics adds world-leading capabilities in surface area, porosity, and particle activity measurements, while SciAps provides portable XRF, LIBS, and NIR analyzers for versatile, in-field elemental analysis.
With a global team of 2,500 employees and local support in 20 countries, we are committed to helping our customers advance innovation while contributing to a cleaner, healthier, and more sustainable world. We aim to achieve Net Zero in our operations by 2030.
Infinitopes
Infinitopes is pioneering a new era in cancer treatment with its Precision Immunomics™ platform, a transformative, off-the-shelf vaccine strategy built on breakthrough immunology and next-generation antigen discovery. Our approach challenges the limitations of personalised vaccines, offering a rapid, cost-effective, and scalable alternative that delivers precision immunotherapy to a broader patient population. By integrating world-leading immunopeptidomics, bespoke AI/ML workflows, clinically validated vectors, and intelligent patient stratification, we aim to unlock the full therapeutic potential of cancer vaccines without the costs, delays, and clinical complexity of fully personalised alternatives. Now a clinical-stage company, Infinitopes is set to commence a Phase I/IIa clinical trial in H2 2025, marking a major milestone in bringing our innovative platform into the clinic.
To learn more about us or for any inquiries, please reach out at info@infinitopes.com
